Proxy Biomedical Announces Proprietary Biomaterial Processing Technology Enabling Breakthrough Resorbable Implantable Orthopaedic Products
Share:
Bio-XT Can Enable Stronger, More Porous, Lower Profile Resorbable Implants to Support Performance and Clinical Outcome Improvements in Next Generation Products
Galway, Ireland - Proxy Biomedical, a leading global innovator in the design, development and manufacturing of biomaterials, today announced Proxy Bio-XT, an innovative, strength reinforcing technology that provides a valuable solution to developers of next generation resorbable orthopaedic products. The proprietary processing technology optimizes the microstructure of biomaterials to enable greater than 100% strength gain in resorbable implantables using the same resorbable material grades as those used in current products.
Proxy Bio-XT processing technology offers a superior platform upon which to develop next generation resorbable orthopaedic products. By achieving strength and toughness increases, Bio-XT can facilitate disruptive innovations in implant design, including:
-Â Â Â Â Â Â Â Â Â Introduction of stronger resorbable products for new indications, for which only non-resorbable products are currently considered suitable.
-Â Â Â Â Â Â Â Â Â Introduction of highly porous products, facilitating osteo-conductivity for higher quality tissue regeneration, without compromising product strength.
-Â Â Â Â Â Â Â Â Â Introduction of lower profile products compared to currently available resorbable products, using less material, without compromising product strength.
"Resorbable implants present a number of clinical benefits for orthopaedic applications but their relatively low inherent strength presents a barrier to new product design and limits the adoption of resorbables in new indications," said Kieran Moloney, vice president of engineering, Proxy Biomedical. "Proxy Bio-XT presents an excellent opportunity to substantially improve the performance of the resorbable implants that are currently on the market."
Performance gains resulting from Proxy Bio-XT are enabled through maximization of the biomaterials' inherent mechanical properties, which are compromised during standard processes such as injection molding and extrusion. Results conclusively indicate that resorbable implants manufactured using Bio-XT were significantly stronger than predicate devices of identical geometry and material grade, with a torsional strength increase of 102%.
Bio-XT can be applied to any resorbable polymer or biocomposite blend, enabling its use for improvements to existing product families which leverage material grades that are well understood by the clinical and regulatory community.
To learn more about Bio-XT processing technology, download the complete white paper at http://proxybiomedical.com/orthopaedics-white-papers/. Proxy Biomedical representatives will be available by appointment at AAOS 2015 March 24-28, 2015 in Las Vegas, NV. To request a briefing, please contact Jordan.bouclin@svmpr.com.
About Proxy Biomedical Limited
Proxy Biomedical Ltd is an Irish based company that specializes in biomaterial solutions for medical implantable products, with a proven track record in innovative design and quality-assured manufacturing. The company offers a full-service solution, from the design and development of key components, to finished devices for world leading tier-one medical device companies who seek a trusted partner to help realise their product development needs. Proxy Biomedical Ltd. is quality assured to ISO 13485:2012 and FDA standards, including certification for the provision of Design Services.
